Tests available for patients on direct oral anticoagulants (DOACs) - anti-Xa assays

Principle

A chromogenic functional assay of factor Xa inhibition
- Patient plasma + known excess FXa + antithrombin (in some kits) + chromogenic substrate
- Residual FXa cleaves the substrate -> colour
- Colour is inversely proportional to drug effect
The result is only meaningful against the right calibrator

Calibrator	Reports
LMWH (enoxaparin)	anti-Xa IU/mL
UFH	anti-Xa IU/mL (different range)
Danaparoid, fondaparinux	drug-specific
DOAC-specific (apixaban, rivaroxaban)	ng/mL drug concentration

A "heparin" anti-Xa run on an apixaban sample gives a number that is qualitative at best - it confirms drug presence, not concentration

Not a measure of bleeding risk
Not a therapeutic target with outcome evidence for DOACs
Not affected by the intrinsic pathway - which is exactly why the APTT fails for LMWH

>500,000 Australians on an oral anticoagulant; DOACs now >80% of new prescriptions
Apixaban and rivaroxaban (anti-Xa) far outnumber dabigatran (anti-IIa)
LMWH remains the anticoagulant of choice in pregnancy and cancer-associated thrombosis
Anti-Xa assays are available in most Australian tertiary laboratories; DOAC-calibrated assays are not universally available after hours - know your local service

Unfractionated heparin - long chains bridge antithrombin to both thrombin (IIa) and Xa
- -> strong anti-IIa effect -> APTT prolonged -> APTT is usable
LMWH - short chains (mean ~4-5 kDa) cannot bridge to thrombin
- -> predominantly anti-Xa (anti-Xa:anti-IIa ~3-4:1)
- -> minimal effect on the APTT
- -> *anti-Xa is the only valid assay*
Fondaparinux - pure synthetic pentasaccharide, anti-Xa only (ratio infinity); no effect on APTT at all

	PT/INR	APTT	TT	Anti-Xa
Rivaroxaban	prolonged (reagent-dependent)	variable	normal	quantitative
Apixaban	often normal even at therapeutic levels	often normal	normal	quantitative
Dabigatran	variable	prolonged	exquisitely sensitive	not applicable

A normal PT and APTT does NOT exclude a therapeutic apixaban level
A normal thrombin time excludes dabigatran; dilute TT or ecarin clotting time quantifies it

Routine monitoring is NOT required. Measure only when:

Renal impairment (CrCl <30 mL/min) - accumulation
Extremes of weight (<50 kg, >120-150 kg, BMI >40)
Pregnancy (changing volume of distribution and renal clearance)
Neonates and children
Unexpected bleeding or thrombosis on treatment
Timing is everything: peak level 4 hours after the SC dose, at steady state (>=3 doses)

### Therapeutic ranges (peak, 4 hr post-dose)

Never for routine dose adjustment. Measure when the answer changes management:

Major or life-threatening bleeding - before giving a reversal agent
Urgent surgery or thrombolysis for stroke
Suspected overdose or accumulation in AKI
Treatment failure - thrombosis on therapy; suspected non-adherence
Extremes of body weight, malabsorption or bariatric surgery
Interacting drugs (P-gp/CYP3A4: rifampicin, carbamazepine, azoles, HIV protease inhibitors)

### Interpretation

<30 ng/mL (some centres <50) -> clinically insignificant anticoagulant effect
- -> thrombolysis or surgery can generally proceed; reversal not indicated
Trough levels are typically 20-150 ng/mL, peak 100-400 ng/mL, but the ranges are expected values, not targets
Report the sample time relative to the last dose or the result is uninterpretable

Antithrombin deficiency -> falsely low anti-Xa for UFH (assays containing exogenous AT are unaffected)
Haemolysis, hyperbilirubinaemia, hypertriglyceridaemia -> chromogenic interference
Delayed processing - platelet factor 4 release neutralises heparin -> falsely low
An anti-Xa in a patient on both LMWH and a DOAC cannot separate the two

Dilute thrombin time / ecarin clotting time - dabigatran
Point-of-care DOAC urine dipstick - qualitative presence, useful in stroke triage

High LMWH anti-Xa with renal impairment -> reduce dose or switch to UFH (shorter half-life, reversible, not renally cleared)
Persistently subtherapeutic in pregnancy -> increase dose; repeat 4 hr peak

Drug	Reversal
UFH	Protamine - full reversal (1 mg per 100 units in the last 2-3 hr)
LMWH	Protamine partially reverses (~60%) - no agent fully reverses LMWH
Fondaparinux	No specific reversal; consider rFVIIa in extremis
Dabigatran	Idarucizumab 5 g IV - complete, rapid, monoclonal Fab
Apixaban/rivaroxaban	Andexanet alfa (decoy FXa) where available; otherwise prothrombin complex concentrate (Prothrombinex-VF) 25-50 units/kg

In Australia, PCC remains the mainstay for factor Xa inhibitor-associated major bleeding - andexanet alfa access is limited
- ANNEXA-I showed better haemostatic efficacy than usual care in intracranial haemorrhage but an excess of thrombotic events
Tranexamic acid, blood products, source control and cessation of the drug in all cases
Charcoal is worth considering if ingestion was within 2-4 hours

DOACs are managed by time and renal function, not by assay (PAUSE study)
- Low bleed risk: omit 1 day; high bleed risk: omit 2 days; longer for dabigatran with CrCl <50
Measure only when the interval cannot be respected - emergency surgery, thrombolysis
Do not bridge DOACs with heparin - it causes bleeding without preventing thrombosis

Renal impairment - dabigatran ~80% renally cleared, rivaroxaban ~33%, apixaban ~27%
Obesity and bariatric surgery (altered absorption; anti-Xa confirmation reasonable)
Pregnancy - LMWH dose requirement rises through gestation; DOACs are contraindicated
Antiphospholipid syndrome - triple-positive APS should be on warfarin, not a DOAC (TRAPS trial)
Mechanical heart valves - DOACs contraindicated (RE-ALIGN)
Heparin-induced thrombocytopenia - danaparoid needs its own calibrator; argatroban is monitored by APTT
Antithrombin deficiency; lupus anticoagulant (interferes with clot-based, not chromogenic, assays)
P-gp and CYP3A4 interacting drugs

No DOAC anti-Xa level has been prospectively validated as a treatment target - there is no evidence that dose-adjusting to a concentration improves outcomes
- -> the assay answers "is there drug on board?", not "is the dose right?"
LMWH anti-Xa monitoring in renal impairment and pregnancy reduces accumulation, though outcome data are limited
Concentration-outcome relationships exist (very high levels -> bleeding; very low -> thrombosis) but with wide overlap between bleeders and non-bleeders
Turnaround time is the practical limit: if the assay will take longer than the patient can wait, treat the bleeding clinically and do not delay reversal

14 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.